Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy

American Journal of Cardiology

Volumn 77, Issue 8, 1996, Pages 551-556

  Mahaffey, Kenneth W ^a   Granger, Christopher B ^b   Collins, Rory ^b   O'Connor, Christopher M ^b   Ohman, E Magnus ^b   Bleich, Stanley D ^b   Col, Jacques J ^b   Califf, Robert M ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANISTREPLASE; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; BOLUS INJECTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0029916513     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89305-8     Document Type: Note

References (24)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
2. Gunnar RM, Passamani ER, Bourdillon PDV, Dixon DW, Fuster V, Karp RB, Kennedy JW, Klocke FJ, Pitt B, Rapaport E, Reeves TJ, Russell RO Jr, Sobel BE, Winters WL Jr. Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/ American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures. J Am Coll Cardiol 1990;16:249-292.
3. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med 1990;323:1433-1437.
4. de Bono DP, Simoons ML, Tijssen J, Arnold AE, Betriu A, Burgersdijk C, Lopez Bescos L, Mueller E, Pfisterer M, Zijlstra F, Verstraete M, Van de Werf F, for the European Cooperative Study Group. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-128.
5. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-1417.
6. O'Connor CM, Meese R, Carney R, Smith J, Conn E, Burks J, Hartman C, Roark S, Shadoff N, Heard M III, Mittler B, Collins G, Navetta F, Leimberger J, Lee K, Califf RM, for the DUCCS Group. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS). J Am Coll Cardiol 1994;23:11-18.
7. Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, O'Neill WW, Califf RM, for The TAMI Study Group. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989;79:281-286.
8. Goldberg RJ, Gore JM, Dalen JE. The role of anticoagulant therapy in acute myocardial infarction. Am Heart J 1984;108:1387-1393.
9. Col J, Decoster O, Harique G, Deligne B, Boland J, Pirenne B, Cheron P, Renkin J. Infusion of heparin conjunct to streptokinase accelerates reperfusion of acute myocardial infarction. Results of a double blind randomized study (OSIRIS) (abstr). Circulation 1992;86(suppl I):I-259.
10. The ISIS Pilot Study Investigators. Randomized factorial trial of high-dose intravenous streptokinase, or oral aspirin and of intravenous heparin in acute myocardial infarction. Eur Heart J 1987;8:634-642.
11. Rapold HJ, de Bono D, Arnold AE, Arnout J, De Cock F, Collen D, Verstraete M. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group. Circulation 1992;85:928-934.
12. MacMahon S, Collins R, Flather M, Knight C, Remvig L, Mortensen S, Godwin J, Yusuf S, Peo R. Heparin in the presence or absence of antiplatelet therapy: an overview of randomized trials in acute myocardial infarction (abstr). Circulation 1992;86(suppl I):I-259.
13. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
14. GISSI-2 (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
15. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-75.
16. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
17. Califf RM, Topol EJ, Van de Werf F, Lee KL, Woodlief L, for the GUSTO Investigators. One year follow-up from the GUSTO I trial (abstr). Circulation 1994;90(pt2):I-325.
18. Hsia J, Kleiman N, Aguirre F, Chaitman BR, Roberts R, Ross AM, for the HART Investigators. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. J Am Coll Cardiol 1992;20:31-35.
19. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes RJ, Topol EJ, for the GUSTO-I Trial Investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I Trial. Circulation 1996;in press.
20. The GUSTO IIA Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.
21. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994;90:1624-1630.
22. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
23. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R, for The TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-791.
24. Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, Califf RM. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-1935.